Beijing Children's Hospital
Beijing, China
NCT Number: NCT03914716
Hemophilia is a genetic condition characterized by marked phenotypic heterogeneity. Bleeding into a joint is the single most important risk factor for the development of hemophilic arthropathy (HA). It is thought that clinical and imaging manifestations of HA are at least partially attributable to genetic polymorphisms unrelated to the hemophilia genotype. Identifying and characterizing biologic factors that could explain differences in susceptibility to joint degeneration of patients with hemophilia would help stratify patients according to the risk of degeneration of their joints and develop personalized therapeutic and prophylactic strategies. This study is conducted in China.
Looking for future studies?
Notify Me4 year–11 year
Male
Interventional
Not applicable
Beijing, China
This will be a 3-year prospective cohort study conducted in a single centre (Beijing Children's Hospital, BCH, China) with a 2-year follow-up of patients Index joints (ankles, elbows and knees) of young Chinese boys with hemophilia A will be evaluated as follows: physical examination every 6 months using the Hemophilia Joint Health Score [HJHS], ultrasound imaging (gray-scale and color Doppler ultrasound [US]), and by laboratory (serum) at baseline, at 6, and 24 months. Magnetic resonance imaging (MRI) scans of index joints will be obtained at baseline, and 24 months. Features that will be captured either quantitatively or semantically in the imaging scans will be aggregated to generate "imaging phenotypes" which will be associated with clusters of co-expressed genes (metagenes) and clinical data.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will have physical, imaging examinations and provide samples for biological markers
Time frame: Between baseline and 24 months
AJBRs will be calculated from prospectively collected joint bleeding logs and clinic records.
Time frame: At baseline, 6 months and 24 months
Assessed by ultrasound
Time frame: Between baseline and 24 months
Assessed by MRI of the joints
Time frame: At baseline, 6 months and 24 months
Assessed by ultrasound
Time frame: Between baseline and 24 months
Assessed by MRI of the joints
Time frame: Every 6 months
Assessed by the Hemophilia Joint Health Score tool (HJHS), version 2.1 - Joint score range: 0 (normal) to 16 (worse outcome).
Time frame: At baseline, 6 months and 24 months
Measured by ELISA (enzyme-linked immunosorbent assay)
Time frame: Between baseline and 24 months
Assessed by the 17-point International Prophylaxis Study Group (IPSG) MRI scale. Score range: 0 to 17 (worse outcome)
Time frame: Between baseline and 24 months
Assessed by the 17-point International Prophylaxis Study Group (IPSG) MRI scale. Score range: 0 to 17 (worse outcome)
Andrea Doria
Other
Radiogenomics: Personalized Imaging of Arthropathy in Boys With Hemophilia in China
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07339410
Behavior, Blood Coagulation Disorders
Van, Turkey (Türkiye)
View Trial DetailsNCT04206033
Arthropathy, Blood Coagulation Disorders
Nantes, France
View Trial DetailsNCT04406519
Arthropathy of Ankle or Foot, Arthropathy of Knee
Van, Bardakcı, Turkey (Türkiye)
View Trial DetailsNCT04309903
Arthropathy Hemophilic, Blood Coagulation Disorders
Adana, Sarıcam, Turkey (Türkiye)
View Trial Details